Background Atezolizumab (anti–programmed death-ligand 1) was approved in the USA,
Europe, and elsewhere for treatment-naive and platinum-treated locally …

Background Patients with metastatic urothelial carcinoma (mUC) who progress after
platinum-based chemotherapy have had few treatment options and uniformly poor …

Atezolizumab is an anti–PD-L1 immune checkpoint inhibitor recommended for the treatment
of locally advanced or metastatic urothelial carcinoma (mUC) after prior platinum-containing …

Background Conventional criteria for tumor progression may not fully reflect the clinical
benefit of immunotherapy or appropriately guide treatment decisions. The phase II …

4523 Background: Platinum-based chemotherapy is a standard first-line approach for mUC,
but many pts are ineligible for cisplatin, and progression is common. Atezo (anti–PD-L1) was …

Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable
safety in previous studies in patients with locally advanced or metastatic platinum-resistant …

METHODS: In IMvigor210 Cohort 2 (NCT02108652), mUC pts who progressed during or
following platinum received atezo 1200 mg IV q3w until loss of clinical benefit per …

323 Background: Atezo is approved in the US for mUC and non-small cell lung cancer after
prior treatment with chemotherapy.> 40% of mUC pts in the Phase 2 IMvigor210 study …

Background Atezolizumab can induce sustained responses in metastatic urothelial
carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab …

Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable
safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma …